Performance
That Delivers

Take OA knee pain relief to another level

Pain Reduction

Powerful OA knee
pain reductions

In a 12-week pivotal trial, maximum
pain relief was achieved with
EUFLEXXA
10 weeks after the 3rd injection2,3*

62% Pain Reduction

Pain reduction began as early as 1-week
post-injection and improved with each
injection:
19% after injection 1 (n=160), 37% after injection
2 (n=159), and 48% after
injection 3 (n=159).2*

The most commonly reported adverse events in
this trial were arthralgia (14/160),
back pain
(8/160), and joint effusion (1/160).2

Nearly two-thirds of patients were pain free* at the end of the study

*Based on % reduction in WOMAC pain score from baseline in a
pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158).
Pain-free defined as symptom-free for the 5 WOMAC pain
questions (with average visual analog scale [VAS] scores of <20 mm).2

Primary endpoint: Mean change from baseline in 5 WOMAC pain
scores (noninferiority vs Synvisc). Synvisc
reduced OA knee pain by 55% (P<0.0001).2

Change from baseline in VAS (100-mm scale) for the average of 5
WOMAC scores.2

OA=osteoarthritis; VAS=visual analog scale; WOMAC=Western
Ontario and McMaster Universities Osteoarthritis Index.

Rescue Medication

In a 12-week pivotal trial,
fewer
subjects needed
rescue medication2,3

  • Among patients with unilateral OA knee pain who avoided pain medication, 51% had received EUFLEXXA (n=34/67) vs 18% who had received Synvisc (n=13/72); P=0.0012*

  • In the overall population (unilateral and bilateral OA of the knee), ~44% more EUFLEXXA patients (62/159) avoided pain medication vs Synvisc patients (43/161); P=0.0132

*In a pivotal trial vs Synvisc; acetaminophen was the only rescue medication provided.2

OA=osteoarthritis.

Repeat Treatment

Treatment that performs and
can be repeated3-5

In the FLEXX trial, the most common treatment
related adverse events were
arthralgia (27/293),
back pain (12/293), and musculoskeletal pain
(6/293).3

In the FLEXX extension, the most common
treatment related adverse events
were arthralgia
(19/219), joint swelling (6/219), and back pain
(6/219).3

Nearly half of EUFLEXXA patients (47%) were pain free at 6 months

*Primary efficacy outcome of the FLEXX trial based on the 50-foot
walk test.4

Open-label extension study of the FLEXX trial (n=219) was not
designed to establish long-term efficacy of
a repeat injection series
of EUFLEXXA.5

OA=osteoarthritis.

Early Treatment

Treat earlier for better results

With EUFLEXXA, patients experienced greater pain reduction, and less stiffness and disability when treated at an earlier stage of OA

*KL=Kellgren-Lawrence grading scale based on radiographical classification of knee osteoarthritis. KL-2
(n=235), KL-3 (n=353).

In a post-hoc analysis of the FLEXX and FLEXX extension trials.

All numbers rounded to the nearest whole number.

OA=osteoarthritis.

Joint Effusions

Low incidence of joint effusions

In a pivotal trial, 1 effusion with EUFLEXXA (n=1, 0.6%) vs 15 effusions with Synvisc (n=13, 8.1%); P=0.0015.2

  • EUFLEXXA is not synthesized from avian protein
    and has not been shown to cause pseudoseptic
    reactions in clinical trials3

  • The most common adverse events were
    arthralgia (11/160), back pain (1/160),
    blood
    pressure increase (3/160), joint effusion
    (1/160), joint swelling (3/160),
    nausea (1/160),
    paresthesia (2/160), feeling of sickness of
    injection (3/160),
    skin irritation (1/160), and
    tenderness in study knee (1/160)3

Extensive real-world experience

OA=osteoarthritis.

Get Joint Venture resources

Reference

  1. 1. Rolling 12 month average of IQVIA claims data based on unique patients (August 2018-August 2019). 2. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162. 3. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 4. Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39(1):1-9. 5. Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage. 2011;19(10):1169-1175. 6. Altman RD, Farrokhyar F, Fierlinger A, et al. Analysis for prognostic factors from a database for the intra-articular hyaluronic acid (Euflexxa) treatment for osteoarthritis of the knee. Cartilage. 2016;7(3):229-237.

Please see Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see FULL PRESCRIBING INFORMATION.

Please see Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [OA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see FULL PRESCRIBING INFORMATION.